What Is Hand-Foot Syndrome After Chemotherapy?

Hand-foot syndrome (HFS), also known as palmar-plantar erythrodysesthesia (PPE), is a common cutaneous adverse effect associated with certain chemotherapy agents and targeted cancer therapies. It typically manifests as symmetric, dose-dependent skin toxicity affecting the palms of the hands and soles of the feet.

The condition arises from leakage of cytotoxic drugs—particularly capecitabine, 5-fluorouracil (5-FU), liposomal doxorubicin, and tyrosine kinase inhibitors such as sorafenib and sunitinib—into the capillaries of weight-bearing and friction-prone areas. This leads to endothelial damage, inflammation, and subsequent epidermal injury. Clinical presentation ranges from mild symptoms—including tingling, numbness, and erythema—to more severe manifestations like painful swelling, desquamation, blistering, fissuring, and ulceration.

HFS is graded using standardized criteria, most commonly the National Cancer Institute’s Common Terminology Criteria for Adverse Events (CTCAE). Grade 1 involves mild sensory changes or erythema without functional impairment; Grade 2 features moderate swelling, peeling, or pain that interferes with daily activities; and Grade 3 denotes severe symptoms—including ulceration, blistering, or debilitating pain—that prevent normal occupational or self-care functions.

Management is primarily supportive and preventive. Key strategies include patient education on minimizing friction and heat exposure, wearing loose-fitting footwear and soft cotton gloves, avoiding prolonged pressure on hands or feet, and applying emollients or urea-based creams. Dose modification or temporary treatment interruption may be required in moderate-to-severe cases. In select patients, prophylactic use of oral pyridoxine (vitamin B6) has been explored, though evidence remains inconclusive.

Early recognition and proactive intervention are critical—not only to alleviate discomfort but also to maintain treatment continuity and optimize oncologic outcomes. Oncology teams routinely monitor patients receiving high-risk agents for early signs of HFS to guide timely clinical decision-making.